Allergan plc (AGN) Stake Lowered by Aperio Group LLC

Aperio Group LLC lowered its holdings in Allergan plc (NYSE:AGN) by 31.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 88,740 shares of the company’s stock after selling 40,298 shares during the quarter. Aperio Group LLC’s holdings in Allergan were worth $14,516,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in AGN. Edgewood Management LLC raised its stake in Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares during the last quarter. Baupost Group LLC MA grew its holdings in Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after buying an additional 531,600 shares during the period. Epoch Investment Partners Inc. grew its holdings in Allergan by 1.0% in the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after buying an additional 17,068 shares during the period. Legal & General Group Plc grew its holdings in Allergan by 5.3% in the 3rd quarter. Legal & General Group Plc now owns 1,739,410 shares of the company’s stock valued at $356,484,000 after buying an additional 87,953 shares during the period. Finally, Iridian Asset Management LLC CT grew its holdings in Allergan by 4.8% in the 4th quarter. Iridian Asset Management LLC CT now owns 1,712,404 shares of the company’s stock valued at $280,115,000 after buying an additional 78,455 shares during the period. 79.76% of the stock is owned by institutional investors.

A number of analysts have recently issued reports on AGN shares. Wells Fargo & Co reiterated an “outperform” rating and set a $258.00 target price on shares of Allergan in a report on Wednesday, October 18th. Sanford C. Bernstein set a $252.00 target price on Allergan and gave the stock a “buy” rating in a report on Wednesday, October 18th. Edward Jones reiterated a “hold” rating on shares of Allergan in a report on Wednesday, October 18th. Mizuho lowered Allergan from a “buy” rating to a “neutral” rating and set a $193.00 price target on the stock. in a research report on Thursday, October 19th. Finally, Citigroup reduced their price target on Allergan from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. Allergan currently has an average rating of “Buy” and an average price target of $227.23.

In other news, Director Chris W. Bodine purchased 3,030 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was bought at an average cost of $164.77 per share, for a total transaction of $499,253.10. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average price of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. Insiders have purchased 17,630 shares of company stock worth $2,890,057 in the last three months. 0.36% of the stock is currently owned by company insiders.

Shares of Allergan plc (NYSE:AGN) traded down $0.63 during trading on Thursday, hitting $166.00. The company had a trading volume of 948,330 shares, compared to its average volume of 3,190,000. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $55,420.00, a PE ratio of -13.84, a PEG ratio of 1.12 and a beta of 1.19. Allergan plc has a twelve month low of $156.00 and a twelve month high of $256.80.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same quarter in the prior year, the company posted $3.90 earnings per share. Allergan’s revenue was up 12.0% on a year-over-year basis. research analysts predict that Allergan plc will post 15.57 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.73%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is currently -23.35%.

TRADEMARK VIOLATION NOTICE: “Allergan plc (AGN) Stake Lowered by Aperio Group LLC” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://weekherald.com/2018/02/15/aperio-group-llc-has-14-52-million-position-in-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply